#Sweden #Stockholm #pharmaceuticals #Sobi #Annual General Meeting

Key Outcomes from Sobi's AGM on May 8, 2025

The Swedish Orphan Biovitrum AB (Sobi®) convened its Annual General Meeting (AGM) on May 8, 2025, a significant event for stakeholders as it set the course for the company's operations in the upcoming year. Here are the main highlights from the meeting:

Adoption of Financial Statements

The shareholders unanimously adopted the profit and loss statements as well as the balance sheets for the financial year ending in 2024. This approval signifies confidence in the company’s financial footing and allows Sobi to carry forward its retained earnings, an essential aspect for future investments and growth.

In addition, the AGM has clarified that the Board members and the Chief Executive Officer are discharged from liability for the past financial year, further cementing the solid governance framework within the company.

Election of Board Members and Auditor

A key agenda item was the election of Board members. The AGM re-elected current Board members including Christophe Bourdon, David Meek, Zlatko Rihter, Helena Saxon, Staffan Schüberg, Filippa Stenberg, and Anders Ullman. Notably, Iris Loew-Friedrich was welcomed as a new Board member, which is expected to bring fresh perspectives and expertise to the team. Moreover, David Meek was re-elected as the chair of the Board of Directors, continuing his leadership role within the organization.

The meeting also saw the re-election of Ernst & Young AB as auditors for Sobi, ensuring continued rigorous oversight of the company’s financial activities.

Directors’ Remuneration and Incentive Programs

Significant discussions took place regarding the remuneration for Board members and auditors, which were approved according to the recommendations from the Nomination Committee. Furthermore, the AGM gave the green light for the implementation of long-term incentive programs that aim to align the interests of the directors with the long-term goals of the company. These programs involve a proposed issue of up to 1,412,788 series C shares and allow for the repurchase of issued shares to manage costs associated with these incentives.

Share Issuance Authorization

One of the standout resolutions involved granting the Board authorization to issue new shares, convertible bonds, or warrants. The AGM stipulated that such issuances should not exceed a total of 39,550,000 shares, which establishes a solid framework for enhancing capital flexibility in future ventures. The approval for transferring shares to cover associated expenditures for incentive programs highlighted Sobi's commitment to managing its resources effectively.

Future Outlook

Overall, the AGM provided essential insights into Sobi’s strategic roadmap moving forward. With a robust governance structure in place and a clear focus on long-term incentives, the company is well-positioned to navigate the challenges ahead in the biopharma landscape. As Sobi continues to unlock breakthroughs for patients with rare diseases, the outcomes from this AGM shall play a pivotal role in shaping its future.

For a detailed account of the resolutions passed during the AGM, stakeholders can refer to the full report available on Sobi's official website.

Sobi is globally recognized for its dedication to biopharmaceutical innovation, striving to enhance the lives of individuals affected by rare diseases. As the company progresses, keen observers will be monitoring its strategic implementations resulting from the AGM resolutions.